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The 52nd Annual Scientific Sessions of the ACC held in
Chicago this spring presented a great deal of new informa-
tion for cardiovascular specialists. Numerous sessions were
held in a variety of topic areas. As a special feature, leaders
were selected to present the highlights of nine topic areas at
a session held on the last day of the meeting. We are pleased
to present here the highlights of the Scientific Sessions as
formulated by the experts in these topics.
Myocardial Infarction and Ischemia
Prediman K. Shah, MD, FACC
Los Angeles, California
On behalf of my colleagues in the Scientific Program
Committee, it is my honor and pleasure to present a few of
the highlights among the scientific presentations at the
annual Scientific Sessions of the American College of
Cardiology, held in March to April 2003, in the category of
Myocardial Infarction and Ischemia. I extend my sincere
apologies to many fine colleagues whose interesting and
important work could not be included in these highlights in
view of time constraints.
Immediate reduction in acute myocardial infarction (MI)
after implementation of a comprehensive smoke-free
ordinance. This study was presented by Dr. Richard Sar-
gent of St. Peter’s Hospital, Helena, Montana, at the Late
Breaking Clinical Trials session. Several studies have shown
that second-hand smoke increases the risk of fatal and
non-fatal cardiac events by as much as 30%. Second-hand
smoke rapidly induces endothelial dysfunction and creates a
prothrombotic state through activation of platelets and
platelet aggregation as well through induction of tissue
factor. The goal of the study was to determine the impact of
enactment of a smoke-free workplace and public place
ordinance on the incidence of acute MI. A municipal
ordinance was enacted on July 4, 2002, banning smoking in
all public places, such as offices, restaurants, bars, and
casinos, in Helena, Montana. In December 2002, the
ordinance was suspended because of legal challenges. Inves-
tigators tracked all patients admitted to the St. Peter’s
Hospital (the primary cardiac care center that serves 65,913
residents in Helena, Montana) with a primary or secondary
diagnosis of acute MI at discharge, for six months after
implementation of the smoke-free ordinance. Similar data
were collected through chart review for a period of four
years before the implementation of the ordinance. Investi-
gators also collected data from hospital records of patients
outside the Helena area that were not affected by the public
ban on smoking. Investigators controlled for long-term
trends and seasonal variation. The effect of smoking ban on
the incidence of acute MI was examined using multilinear
regression analysis. During an average six-month period
before the enactment of the ordinance, approximately seven
patients with acute MI were admitted per month to
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St. Peter’s Hospital, whereas during the average six months
after the enactment of the smoking ban, the number of
admissions for acute MI per month dropped to approxi-
mately three, representing a nearly 60% reduction (p 
0.02). In contrast, there was no significant change in the
number of admissions for acute MI among people living
outside the smoke-free ordinance zone. The important
observations from this population-based study reinforce the
relatively large and rapid benefits of implementing clean
indoor air legislation on cardiovascular health, further con-
firming the adverse health impact of second-hand smoke.
Therefore, this study provides data of considerable public
health value.
Effect of glucose, insulin, and potassium (GIK) on
30-day mortality, infarct size, and ejection fraction in
patients with acute MI undergoing primary percutaneous
transluminal coronary angioplasty (PTCA). The concept
of GIK or the polarizing solution was introduced four
decades ago by the Mexican cardiologist, Dimitri Sodi-
Pallares, as an antiarrhythmic intervention with the putative
mechanism of membrane stabilization. Since its original
introduction 40 years ago, this form of treatment has also
been evaluated for infarct size and mortality reduction in
several small randomized trials which have yielded conflict-
ing results, casting doubt on the efficacy of this intervention.
In this study, presented by Iwan C. Van der Horst,
investigators from the Netherlands examined the effect of
intravenous GIK in combination with reperfusion therapy
using primary PTCA on clinical outcome, left ventricular
function (using radionuclide ventriculography) and infarct
size (using cumulative release of the cardiac enzyme lactic
dehydrogenase) in 940 patients with acute MI. Nearly half
received a placebo (n  464), and the other half received
GIK (n  476). Overall, there was no effect of GIK on
mortality (4.8% vs. 5.8%; p 0.5); however, in 856 patients
without evidence of clinical left ventricular failure, the
mortality was significantly lower with GIK compared with
placebo (1.2% vs. 4.2%; p  0.005). The prevalence of the
highest quartile of infarct size was also significantly lower
among GIK recipients (22% vs. 29%; p  0.005), who also
tended to have a lower prevalence of left ventricular dys-
function ejection fraction below 30% (13% vs. 17%; p 
0.2). This randomized trial has brought us full-circle back to
GIK as a potentially low-cost, low-risk adjunctive interven-
tion in a subset of patients with acute MI undergoing
mechanical reperfusion. Although the results appear prom-
ising, more studies are warranted to confirm the results
presented by these investigators.
The Aggrastat to Zocor (A to Z) trial. This late-breaking
randomized clinical trial was sponsored by Merck and
Company. It was presented by Dr. Michael Blazing of Duke
University Medical Center (Durham, North Carolina). This
study was designed in two parts. In part 1 of the study, the
investigators compared the clinical outcome of 3,987 high-
risk (with electrocardiogram changes or a positive biomar-
ker) patients with acute coronary syndromes, all of whom
were receiving aspirin and tirofiban (Aggrastat, a short-
acting intravenous IIb/IIIa inhibitor), randomly allocated to
weight-adjusted, unfractionated, intravenous heparin
(UFH) or to subcutaneous injection of low-molecular-
weight heparin enoxaparin at 1 mg/kg/12 h. The allocated
heparin treatment was given for 120 h but could be stopped
or switched at the discretion of the treating physician. Of
the patients, 60% underwent coronary angiography during
the hospital admission. The trial was designed as a non-
inferiority trial comparing enoxaparin to UFH. The primary
end point of death/MI/refractory ischemia occurred slightly
more frequently in the UFH group, but this was not
statistically significant (9.4% vs. 8.9%; p  0.23). The
overall results fulfilled the prespecified requirements to show
that enoxaparin was not inferior to UFH. None of the
subgroup analyses revealed any statistically significant dif-
ferences between UFH and enoxaparin. Secondary end
points, while showing a slight trend in favor of enoxaparin,
were also not statistically significantly different between the
two groups. There was a slight trend towards increased
major plus minor bleeding with enoxaparin compared with
UFH, but the differences, once again, were not statistically
significant (3.1% vs. 2.2%; pNS). Therefore, these overall
results support the equivalence of UFH and enoxaparin in
terms of benefits and risks in acute coronary syndrome
patients. However, logistic advantages, in terms of feasibil-
ity for subcutaneous use, lack of need for dose adjustment,
and monitoring with blood tests, would tend to favor
enoxaparin over UFH. Part 2 of this trial, which compares
early versus late initiation of simvastatin (Zocor) therapy, is
likely to be presented later this year at the American Heart
Association meetings in November 2003.
Efficacy of a novel P-selectin antagonist, rPSGL-Ig,
for reperfusion therapy in acute MI: the RAPSODY
trial. P-selectin is an adhesion molecule that interacts with
its ligand P-selectin glycoprotein ligand (PSGL) and me-
diates the endothelium-leukocytes and platelets-leukocytes
interaction. It has been implicated in thrombosis as well as
so-called “reperfusion injury.” Reperfusion injury is a puta-
tive and highly controversial concept that implicates reper-
fusion as a source of myocardial damage through the release
of oxygen-free radicals and leukocyte-plugging of microvas-
culature. In experimental studies, a recombinant inhibitor of
P-selectin, rPSGL-Ig, has been shown to facilitate throm-
bolysis, reduce reocclusion, and attenuate “reperfusion inju-
ry.” This dose-finding randomized clinical trial, conducted
in 598 ST-segment elevation type acute MI patients receiv-
ing tissue plasminogen activator for reperfusion therapy
within 6 h of onset of symptoms, was designed to determine
if rPSGL-Ig would improve the speed of ST-segment
resolution (as a surrogate for facilitation of thrombolysis)
and reduce infarct size. Three different doses of intravenous
rPSGL-Ig (5 mg, 25 mg, 75 mg) were compared with
placebo. Continuous ST-segment monitoring was used to
assess reperfusion; infarct size was measured by sestamibi
single photon emission computed tomography imaging on
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day 7; and left ventricular ejection fraction was determined
by radionuclide ventriculography on day 30. Clinical out-
come was monitored for six months. The study was sup-
ported by Wyeth Pharmaceuticals and presented by Jean-
Francois Tanguay of the Montreal Heart Institute
(Montreal, Quebec, Canada). The study failed to show any
significant effect of any dose of rPSGL-Ig on infarct size,
ejection fraction, and stroke/death/MI at 30 or 180 days.
Furthermore, and contrary to expectation, there was a
significant prolongation of time to ST-segment resolution
with increasing doses of rPSGL-Ig (p  0.008). Therefore,
this study failed to show any benefit with adjunctive use of
a novel P-selectin antagonist, and adds to a large body of
clinical trial data (conducted at an astronomical expense)
that have failed to show any benefit from any intervention
designed to address the so-called “reperfusion injury” de-
spite promising preclinical findings. These observations
continue to question the very existence of so-called “reper-
fusion injury,” as suggested by elegant experimental studies
of William Ganz at Cedars Sinai Medical Center (Los
Angeles, California) reported several years ago.
Regional angiogenesis with vascular endothelial growth
factor (VEGF): the RAVE trial. The concept of thera-
peutic angiogenesis for relief of ischemia, using angiogenic
growth factor gene transfer, first pioneered by the late Dr.
Jeffrey Isner, continues to be explored despite inconsistent
and conflicting results. The RAVE trial was a double-blind,
randomized, placebo-controlled trial to assess the safety and
efficacy of locally administered adenovirus-mediated
VEGF-121 (Ad-VEGF-121) gene transfer for unilateral
peripheral vascular disease in patients with severe disabling
intermittent claudication. The study was presented by Dr.
Sanjay Rajagopalan of the University of Michigan (Ann
Arbor, Michigan). Twenty local and ipsilateral intramuscu-
lar injections of either low dose or high dose of Ad-VEGF-
121 were compared with placebo injections in 105 patients
with severely symptomatic peripheral vascular disease con-
fined to one lower extremity. The primary end point was
safety and peak walking time at 12 weeks after randomiza-
tion. Secondary end points included ankle-brachial index
and peak walking time at 26 and 52 weeks.
The Ad-VEGF-121 therapy resulted in a dose-
dependent increase in leg edema (nearly 30% at high dose)
without any excess of cellulitis or liver function abnormal-
ities. However, Ad-VEGF-121, at any dose, failed to
produce any significant improvement over placebo in the
primary end point. Placebo-treated patients showed a 20%
increase in peak walking time at 12 weeks, which was not
significantly different from the 30% and 20% increases
experienced by low- and high-dose gene therapy recipients,
respectively. Similarly, there was no significant difference in
secondary end points or any other quality-of-life measures
between placebo and gene therapy recipients. These results
from the largest placebo-controlled adenoviral gene transfer
trial in cardiovascular disease to date were quite disappoint-
ing, adding to the uncertainty of this seemingly biologically
plausible and promising approach for refractory organ isch-
emia. The lack of beneficial effects may have been due to an
inadequate dose of Ad-VEGF-121, limited transcription of
the therapeutic gene, and/or limited duration of gene
transcription, which has been a problem with adenoviral
vectors. Whether better vectors, different angiogenic growth
factors, or different delivery systems will ultimately allow
realization of the promise of angiogenic gene therapy
remains an open question for now.
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Vascular Disease, Hypertension, and
Prevention: “From Endothelium to Clinical Events”
Alan T. Hirsch, MD
Minneapolis, Minnesota
The Vascular-Hypertension-Prevention (VHP) track
bridges the best data from vascular biology, thrombosis,
cardiovascular epidemiology, hypertension, and lipid-
modifying clinical trials and offers insights into optimal
treatment of coronary, cerebrovascular, and peripheral arte-
rial disease (PAD). This is a form of “translational medi-
cine” that extends knowledge “from the vascular endothe-
lium to clinical cardiovascular events.” The VHP track has
demonstrated that a better understanding of vascular biol-
ogy can improve cardiovascular health. New insights from
clinical practice can guide a search for biologic mechanisms,
just as improved understanding of vascular mechanisms can
guide improved practice. Abstracts in this arena now rep-
resent an increasingly large component (18%) of the Annual
Scientific Sessions.
THE FIRST VASCULAR SPOTLIGHT SESSION
In recognition of rapid scientific expansion, broad scope,
and clinical relevance of the VHP initiative, the meeting
From the Vascular Medicine Program, Cardiovascular Division, Minnesota Vas-
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